Search
                    Arizona Paid Clinical Trials
A listing of 1697  clinical trials  in Arizona  actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
            1189 - 1200 of 1697
        
                Arizona is currently home to 1697 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Phoenix, Tucson, Scottsdale and Mesa. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
            
                                                Featured Trial
                
                Healthy Participants Needed (Colonoscopy + Cancer Screening)
            
        Recruiting
            
        Earn $325 - $475 in electronic payment card compensation for your time and effort by participating in a clinical study to develop a blood test that may one day help screen for colon cancer. Take a quick quiz to see if you qualify.
    
    
                            Conditions: 
                                    
        
            
                        Healthy
                    
                                    
                        Healthy Volunteers
                    
                                    
                        Healthy Subjects
                    
                                    
                        Healthy Volunteer
                    
                                    
                        Healthy Participants
                    
                                    Featured Offer
                
                Lose Weight with GLP-1 Medications
            
        Recruiting
            
        Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®. 
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $50 off your first program with code policy-lab-50.
    GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $50 off your first program with code policy-lab-50.
                            Conditions: 
                                    
        
            
                        Overweight
                    
                                    
                        Overweight and Obesity
                    
                                    
                        Obesity
                    
                                    
                        Weight Loss
                    
                                    
                        Morbid Obesity
                    
                                    Featured Trial
                
                Stroke Clinical Study
            
        Recruiting
            
        A clinical study for people that suffer with Stroke
    
    
                            Conditions: 
                                    
        
            
                        Stroke
                    
                                    Featured Trial
                
                Chronic Kidney Disease (CKD) Clinical Study
            
        Recruiting
            
        A clinical study for people that suffer with Chronic Kidney Disease (CKD)
    
    
                            Conditions: 
                                    
        
            
                        Chronic Kidney Disease (CKD)
                    
                                    Featured Trial
                
                Ischemic heart disease (IHD) Clinical Study
            
        Recruiting
            
        A clinical study for people that suffer with Ischemic heart disease (IHD)
    
    
                            Conditions: 
                                    
        
            
                        Ischemic heart disease (IHD)
                    
                                    
                
                                    Prospective, Multicenter, Case-Control Analysis of the VersaTie Posterior Fixation System to Prevent Proximal Junctional Failure in Long Posterior Spinal Fusion Constructs for Adult Patients
                                
            
            
        Recruiting
                            
            
                Prospective, Multicenter, Case-Control Analysis of the VersaTie Posterior Fixation System to Prevent Proximal Junctional Failure in Long Posterior Spinal Fusion Constructs for Adult Patients             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                04/28/2025
            
            Locations: Barrow Neurological Institute, Phoenix, Arizona         
        
        
            Conditions: Adult Spinal Deformity, Scoliosis, Kyphosis
        
            
        
    
                
                                    Registry of Participants With Generalized Myasthenia Gravis Treated With Alexion C5 Inhibition Therapies (C5ITs)
                                
            
            
        Recruiting
                            
            
                Long-term, multicenter, multinational, observational, registry of patients with gMG that is designed to collect data on clinical outcomes and safety in patients prescribed Alexion C5 inhibitor therapies (C5IT) such as eculizumab (Soliris®) and ravulizumab (Ultomiris®).             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                04/28/2025
            
            Locations: Clinical Trial Site, Scottsdale, Arizona         
        
        
            Conditions: Generalized Myasthenia Gravis
        
            
        
    
                
                                    An Observational Study of Patients With Chronic Hepatitis B (CHB) Infection
                                
            
            
        Recruiting
                            
            
                The TARGET-HBV study engages an observational research design to conduct a comprehensive review of outcomes for patients with CHB infection. The initial phase of the study that enrolled patients treated with tenofovir alafenamide (TAF) was successfully completed. The current protocol (Amendment 1) describes the second phase of the study that will engage research activities for patients being managed for CHB in usual clinical practice in the US and Canada. The study addresses important clinical q...  Read More             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                04/28/2025
            
            Locations: Banner University Medical Center Phoenix, Phoenix, Arizona         
        
        
            
        
    
                
                                    Reducing Dropout and Improving Outcomes From PTSD Therapy: When to Switch Therapies or Stay the Course
                                
            
            
        Recruiting
                            
            
                Investigators' overall objective is to compare methods of identifying individuals who may be experiencing challenges in Cognitive Processing Therapy (CPT) and compare methods of intervening to optimize treatment retention and outcomes. Investigators' specific aims are:
1. to determine whether the use of CPT skills versus collaboratively considering switching to Present Centered Therapy (PCT) is more effective in improving outcomes for individuals experiencing challenges with CPT. Outcomes inclu...  Read More             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                04/25/2025
            
            Locations: VA Phoenix Health Care System, Phoenix, Arizona         
        
        
            Conditions: Post Traumatic Stress Disorder
        
            
        
    
                
                                    Evaluate REC-4881 in Patients With FAP
                                
            
            
        Recruiting
                            
            
                This is a multicenter, two-part trial in participants with Familial Adenomatous Polyposis (FAP).             
        
        
    Gender:
                ALL
            Ages:
                55 years and above
            Trial Updated:
                04/24/2025
            
            Locations: Mayo Clinic - Scottsdale, Scottsdale, Arizona         
        
        
            Conditions: Familial Adenomatous Polyposis
        
            
        
    
                
                                    Effect of a Fermented Dairy Protein With Prebiotic Fiber on GI Complaints
                                
            
            
        Recruiting
                            
            
                A positive impact of a fermented dairy protein with prebiotic fiber supplement on self-reported GI complaints and wellbeing has been suggested (Wardenaar et al. 2024). The following project aims to further investigate the impact of this supplements in athletes with and without GI complaints in two separate data collections.
Part I of the data collection aims to investigate the impact of this supplement vs. a placebo on carbohydrate malabsorption (as a potential cause for GI distress) in athlete...  Read More             
        
        
    Gender:
                ALL
            Ages:
                Between 18 years and 50 years
            Trial Updated:
                04/23/2025
            
            Locations: ASU Health Futures Center, Phoenix, Arizona         
        
        
            Conditions: Digestive Health, Quality of Life
        
            
        
    
                
                                    A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis
                                
            
            
        Recruiting
                            
            
                A randomized, double-blind, placebo-controlled clinical study to evaluate the safety and efficacy of 2 doses of inhaled pirfenidone (AP01) versus placebo on top of standard of care in participants with PPF over 52 weeks.             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                04/23/2025
            
            Locations: Pulmonary Associates, PA, Phoenix, Arizona         
        
        
            Conditions: Progressive Pulmonary Fibrosis
        
            
        
    
                
                                    LS301-IT in Partial Mastectomy and Sentinel Lymph Node Biopsy (SLNB) for DCIS or Stage I-II Primary Invasive Breast Cancer
                                
            
            
        Recruiting
                            
            
                The aim of this Phase 1b/2 study is to investigate the safety, efficacy, and pharmacokinetics (PK) of a single dose of LS301-IT, a novel fluorescence imaging agent developed by Integro Theranostics (IT), administered by intravenous (IV) injection in female patients undergoing partial mastectomy for DCIS (whether or not undergoing planned SLNB) or Stage I-II primary invasive breast cancer undergoing SLNB. Safety is the primary objective of this study, followed by efficacy that will be assessed fr...  Read More             
        
        
    Gender:
                FEMALE
            Ages:
                Between 18 years and 80 years
            Trial Updated:
                04/23/2025
            
            Locations: Integro Theranostics Research Site #2, Scottsdale, Arizona         
        
        
            
        
    
                
                                    A Study to Assess Adverse Events of Intravenously (IV) Infused ABBV-383 in Adult Participants With Relapsed or Refractory Multiple Myeloma
                                
            
            
        Recruiting
                            
            
                Multiple Myeloma (MM) is a cancer of the blood's plasma cells ( blood cell). The cancer is typically found in the bones and bone marrow (the spongy tissue inside of the bones) and can cause bone pain, fractures, infections, weaker bones, and kidney failure. Treatments are available, but MM can come back (relapsed) or may not get better (refractory) with treatment. This is a study to determine adverse events and change in disease symptoms of ABBV-383 in adult participants with relapsed/refractory...  Read More             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                04/23/2025
            
            Locations: Mayo Clinic Arizona /ID# 251405, Phoenix, Arizona         
        
        
            Conditions: Multiple Myeloma
        
            
        
    
                
                                    Pulmonary Hemodynamics During Exercise - Research Network
                                
            
            
        Recruiting
                            
            
                The purpose of this Clinical Research Collaboration is to investigate the prognostic implications of pulmonary hemodynamics during exercise based on a large scale multi-centre approach by using retrospective and prospective analysis of hemodynamic data.             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                04/23/2025
            
            Locations: University of Arizona, Banner University Medical Center, Phoenix, Arizona         
        
        
            Conditions: Pulmonary Circulation Diseases
        
            
        
    
                
                                    A Study of LY4170156 in Participants With Selected Advanced Solid Tumors
                                
            
            
        Recruiting
                            
            
                The purpose of this study is to find out whether the study drug, LY4170156, is safe, tolerable and effective in participants with advanced solid tumors. The study is conducted in two parts - phase Ia (dose-escalation, dose-optimization) and phase Ib (dose-expansion). The study will last up to approximately 4 years.             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                04/22/2025
            
            Locations: Honor Health Research Institute, Scottsdale, Arizona         
        
        
            Conditions: Ovarian Neoplasms, Endometrial Neoplasms, Uterine Cervical Neoplasms, Carcinoma, Non-Small-Cell Lung, Triple Negative Breast Neoplasms, Pancreatic Neoplasm, Colorectal Neoplasms
        
            
        
    
                
                                    Conditioning SCID Infants Diagnosed Early
                                
            
            
        Recruiting
                            
            
                The investigators want to study if lower doses of chemotherapy will help babies with SCID to achieve good immunity with less short and long-term risks of complications after transplantation. This trial identifies babies with types of immune deficiencies that are most likely to succeed with this approach and offers them transplant early in life before they get severe infections or later if their infections are under control. It includes only patients receiving unrelated or mismatched related dono...  Read More             
        
        
    Gender:
                ALL
            Ages:
                Between 0 years and 2 years
            Trial Updated:
                04/22/2025
            
            Locations: Mayo Clinic Arizona and Phoenix Children's Hospital, Phoenix, Arizona         
        
        
            Conditions: SCID
        
            
        
    